Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept

Changes in serum cartilage oligomeric matrix protein (COMP) were studied during a 6-month period from initiation of treatment of rheumatoid arthritis patients with either infliximab or etanercept, to elucidate whether the favourable results of tissue protection reported in clinical trials are corrob...

Descripción completa

Detalles Bibliográficos
Autores principales: Crnkic, Meliha, Månsson, Bengt, Larsson, Lotta, Geborek, Pierre, Heinegård, Dick, Saxne, Tore
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2003
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC165057/
https://www.ncbi.nlm.nih.gov/pubmed/12823852
http://dx.doi.org/10.1186/ar760

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC165057/
https://www.ncbi.nlm.nih.gov/pubmed/12823852
http://dx.doi.org/10.1186/ar760

Ejemplares similares